FDA Will Take Action On Biosimilars Delayed By Inspection Lag

US Agency Says It Is ‘Actively Working’ On Addressing Outstanding Inspections

 
• By David Wallace
  
COVID-19 coronavirus tape barrier
The pandemic has acted as a barrier to FDA inspections • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products